Start the New Year off right with Startup Grind Frederick! Join us for an interesting and motivational Fireside Chat featuring Darryl Sampey, PhD. and Co-Founder, CEO & President of BioFactura, a leader in biopharmaceutical development and manufacturing.
Darryl will share with us his unique journey from eight years as lead singer in a Rock & Roll band to his founding, developing and leading BioFactura. Specifically, he will focus on:
• What his “rock” experience taught him in leading his company;
• Challenges of establishing a business in a new market;
• The necessities of persistence, flexibility and innovation for early stage survival;
• Defining excellence in a highly competitive market;
• Short- and long-term planning for success;
• Developing a highly professional staff; and
• Questions from participants.
In the Startup Grind tradition, we'll begin the evening with fun, food and connecting with friends.
You’ll meet with like-minded people to share what's on your mind regarding your business and inspire others with new ideas.
Startup Grind is truly passionate about helping business founders, entrepreneurs and startups succeed. We intend to make the startup journey less lonely, more connected and more memorable. Join Startup Grind Frederick and RSVP today!
We look forward to seeing you there!
Darryl Sampey co-founded BioFactura in 2004 and as President and CEO manages all strategic and scientific endeavors of the Company including partnership/alliance building, fundraising, intellectual property maintenance, contract research and development, platform technology programs, and biopharmaceutical product development.Read More
Darryl Sampey founded BioFactura and manages all strategic and scientific endeavors of the Company including business development, contract research and development, platform technology programs, and biopharmaceutical product development.
Before BioFactura, he led both process development and manufacturing teams at Human Genome Sciences, Inc. (HGS). Dr. Sampey joined the protein development department of HGS in 1998, and honed his skills developing new biologics processes and control strategies. During his tenure with HGS, Dr. Sampey played key roles in the start-up, commissioning, and validation of the company’s first cGMP manufacturing facility and associated development laboratories. Additionally, he performed lead roles in the development, transfer, and evaluation of novel fermentation processes for cGMP clinical manufacturing.
Prior to his work at HGS, Dr. Sampey gained industrial experience in the commercial research laboratory designing and optimizing fermentation and product recovery processes for novel vaccines at North American Vaccine, Inc. His work in vaccine research has since progressed to internationally-approved vaccines for whooping cough in infants and meningitis in adults.
Darryl Sampey began his career in biotechnology at the University of Maryland. During his undergraduate years, Dr. Sampey pursued independent research in novel protein analysis technique under the advisement of Dr. William Bentley. Dr. Sampey graduated first in his class and was awarded a Bachelor of Science in Chemical Engineering, Magna Cum Laude, and subsequently earned a Ph.D. in Bioengineering both from the University of Maryland.